Exelixis, Inc. $EXEL Shares Acquired by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 12.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,557 shares of the biotechnology company’s stock after purchasing an additional 11,993 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Exelixis were worth $4,696,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Frank Rimerman Advisors LLC grew its stake in Exelixis by 4.7% during the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 285 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Exelixis by 6.1% during the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 307 shares in the last quarter. Rathbones Group PLC grew its stake in Exelixis by 5.3% during the 1st quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company’s stock worth $253,000 after purchasing an additional 347 shares in the last quarter. Larson Financial Group LLC grew its stake in Exelixis by 9.2% during the 1st quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 367 shares in the last quarter. Finally, Byrne Asset Management LLC grew its stake in Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 400 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on EXEL shares. Wall Street Zen downgraded Exelixis from a “buy” rating to a “hold” rating in a report on Monday, September 15th. Jefferies Financial Group set a $50.00 price target on Exelixis and gave the stock a “buy” rating in a report on Tuesday, June 24th. UBS Group set a $38.00 price target on Exelixis and gave the stock a “neutral” rating in a report on Wednesday, July 30th. Stephens raised Exelixis from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $29.00 to $60.00 in a report on Tuesday, June 24th. Finally, The Goldman Sachs Group started coverage on Exelixis in a report on Wednesday, September 17th. They set a “buy” rating and a $47.00 price target for the company. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.42.

Exelixis Stock Up 3.9%

Shares of EXEL stock opened at $40.57 on Tuesday. The stock has a market capitalization of $10.92 billion, a PE ratio of 19.50, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. Exelixis, Inc. has a 52-week low of $25.17 and a 52-week high of $49.62. The stock’s 50-day moving average price is $38.89 and its 200 day moving average price is $39.78.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. The firm had revenue of $568.26 million for the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. Analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.